PMID- 15916692
OWN - NLM
STAT- MEDLINE
DCOM- 20050801
LR  - 20081121
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 129
IP  - 5
DP  - 2005 Jun
TI  - Fusion of dendritic cells with multiple myeloma cells results in maturation and 
      enhanced antigen presentation.
PG  - 687-700
AB  - Dendritic cells (DCs) are potent antigen-presenting cells that are uniquely 
      capable of inducing primary immune responses. Although tumour cells may directly 
      inhibit DC maturation, exposure to tumour products may also result in their 
      activation. Fusions of cancer cells and DCs are being explored as cancer 
      vaccines. The effect of tumour cell fusion on DC maturation and their functional 
      characteristics has not been defined. In the present study, immature and mature 
      DC generated from human CD34+ and peripheral blood precursors were fused to 
      multiple myeloma cells in the presence of polyethylene glycol. Fusion of both 
      immature and mature DCs with tumour cells resulted in an activated phenotype. In 
      this regard, fusion cells expressed interleukin-12, a cytokine essential for the 
      induction of T-helper cell type 1 immunity. In contrast to immature DCs, fusion 
      cells also strongly expressed CC-chemokine receptor R7, which is responsible for 
      DC migration to draining lymph nodes. Fusions generated with both immature and 
      mature DCs also potently stimulated T-cell expression of gamma-interferon and 
      cytotoxic T lymphocyte killing of tumour targets. These findings demonstrate that 
      tumour cell fusion induces DC maturation and the development of an activated 
      phenotype necessary for their effectiveness as cancer vaccines.
FAU - Vasir, Baldev
AU  - Vasir B
AD  - Department of Medical Oncology and Dana-Farber/Harvard Cancer Center, Dana Farber 
      Cancer Institute, Boston, MA 02115, USA. david_vasir@dfci.harvard.edu
FAU - Borges, Virginia
AU  - Borges V
FAU - Wu, Zekui
AU  - Wu Z
FAU - Grosman, Daren
AU  - Grosman D
FAU - Rosenblatt, Jacalyn
AU  - Rosenblatt J
FAU - Irie, Masaki
AU  - Irie M
FAU - Anderson, Kenneth
AU  - Anderson K
FAU - Kufe, Donald
AU  - Kufe D
FAU - Avigan, David
AU  - Avigan D
LA  - eng
GR  - P01 CA78378-05/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Antigens, CD34)
RN  - 0 (CCR7 protein, human)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Receptors, CCR7)
RN  - 0 (Receptors, Chemokine)
RN  - 130068-27-8 (Interleukin-10)
RN  - 187348-17-0 (Interleukin-12)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - *Antigen Presentation
MH  - Antigens, CD34/immunology
MH  - *Cancer Vaccines
MH  - Cell Fusion
MH  - Cytotoxicity Tests, Immunologic
MH  - Dendritic Cells/*cytology
MH  - Flow Cytometry
MH  - Humans
MH  - Hybrid Cells
MH  - Interferon-gamma/immunology
MH  - Interleukin-10/immunology
MH  - Interleukin-12/immunology
MH  - Lymphocyte Activation
MH  - Lymphocyte Culture Test, Mixed
MH  - Multiple Myeloma/*immunology/*pathology
MH  - Receptors, CCR7
MH  - Receptors, Chemokine/immunology
MH  - T-Lymphocytes/immunology
EDAT- 2005/05/27 09:00
MHDA- 2005/08/02 09:00
CRDT- 2005/05/27 09:00
PHST- 2005/05/27 09:00 [pubmed]
PHST- 2005/08/02 09:00 [medline]
PHST- 2005/05/27 09:00 [entrez]
AID - BJH5507 [pii]
AID - 10.1111/j.1365-2141.2005.05507.x [doi]
PST - ppublish
SO  - Br J Haematol. 2005 Jun;129(5):687-700. doi: 10.1111/j.1365-2141.2005.05507.x.